Poststelle (BMJV)

Von:

Joerg Thomaier <

Gesendet:

Mittwoch, 28. September 2016 09:41

An: Cc: Bundesministenum der Justiz und für Verbraucherschutz Abt III lögf III

.//...Anlagen

Maas, Heiko (Minister) Poststelle (BMJV)

Petreff: Anlagen:

2 8. 09. 2016 1 2 4 5 Join

Joint Industry Letter - Unitary Patent and Unified Patent Court

JointIndustryLetter.pdf

Dear Mr Maas

Please find attached a joint letter of pharmaceutical companies and associations. I am writing to you on behalf of the undersigning companies which found it timely to give a clear message in support of the unitary patent system and urge that it should enter into force as planned.

Yours sincerely, Jörg Thomaier

Dr. Jörg Thomaier
Bayer Intellectual Property GmbH
Geb. 4865, R. 437
Creative Campus Monheim
Alfred-Nobel-Straße 10
D-40789 Monheim
Phone: +49 2173 38

+49 2173 38 969

Fax: E-Mail:

Web: http://www.bayer.com

Managing Directors: Joerg Thomaier | Michael Reinartz

Place of Business: Monheim am Rhein | Amtsgericht Düsseldorf, HRB 67604

TITS 4
GG | AE | BER | v. Abg. | Abl.
Blindesministerium der Justiz
und für Verbraucherschutz
Eingang: 2 & Sep. 2016

Ministerbüro

Min. PSt J PSt V St J St V LM PR PRÖA

Heron Karder (2)

1 C 7/10

all Who

September 28th, 2016

Joint Industry Letter - Unitary Patent and Unified Patent Court

The undersigned companies and associations in the pharmaceutical sector hereby make the following joint statement regarding the Unitary Patent package that is the Unitary Patent and the Unified Patent Court. Our companies are committed to research, development and manufacture in Europe of medicinal products for human use.

The pharmaceutical industry is highly regulated. The development of a new medicine and the need for market authorisation to bring a new medicine to the market takes many years and entails very significant costs, without any certainty of a positive outcome. Therefore, the pharmaceutical industry is heavily dependent on an effective patent system protecting its innovations for a certain period of time.

The introduction of the Unitary Patent and the Unified Patent Court will significantly simplify the patent system in Europe and reduce the costs for obtaining, maintaining and enforcing patents. We support and welcome this reform.

The governmental, legal and practical preparations needed for the reform are advanced or finalised within the participating States, in the Select Committee and in the Preparatory Committee, as well as on the side of industry. Very large efforts have led to this present stage.


In the wake of the political unrest seen in Europe in the summer, we find it timely to give a clear message to responsible politicians that we, the signing companies and industry associations, welcome the new patent system and urge that it should enter into force as planned. The attractiveness of the system would increase with a long-term participation of the United Kingdom. Therefore we also urge that solutions for such inclusiveness are considered.

Very truly yours,


The undersigning pharmaceutical companies and associations




Bayer AG, Germany



Boehringer Ingelheim GmbH, Germany



Merck KGaA, Germany









Union Chimique Belge, UCB S.A., Belgium



Swedish Association of the Pharmaceutical Industry, Sweden